Oxford Nanopore Demonstrates Label-Free Method for DNA Sequencing



Loading...

By Kevin Davies

February 22, 2009 | In an important paper published online this week in the journal Nature Nanotechnology, scientists at Oxford Nanopore Technologies present the first proof-of-principle of their label-free next-generation sequencing system.

The paper*, by James Clarke and colleagues, shows that an engineered nanopore complex can discriminate between the four bases of DNA (A, C, T and G) with remarkable specificity, and can even identify methylated C residues (“the fifth base”) for good measure. The senior author of the report is Hagan Bayley, Oxford University chemistry professor and co-founder of Oxford Nanopore, who has been leading research into nanopores as detectors for sequencing and other applications for over a decade.

There is immense appeal in a DNA sequencing technology that dispenses with fluorescently tagged molecules, CCD cameras, and expensive microscopes, and thus has the makings of an affordable, real-time, label-free sequencing system. The Oxford Nanopore Nature Nanotechnology paper does not go so far as describing a prototype device or even reading the sequence of a DNA molecule. But it does is show that Oxford scientists have engineered the alpha-hemolysin nanopore to the point that it can efficiently discriminate between the four natural bases of DNA at speeds suitable for high-throughput applications.

Oxford Figure
Nanopores have shown considerable potential for DNA sequencing for more than a decade, but single-stranded DNA molecules slide through the nanopore much too quickly to recognize individual bases. Taking a different tack, Bayley’s group showed a few years ago that it could partially identify individual bases as they dropped through a nanopore by the degree to which they impeded the current flowing across the membrane housing the nanopore.

Building upon that work, Clarke and coworkers genetically engineered the alpha-hemolysin to find the best location to covalently attach a molecule of cyclodextrin -- a kind of washer that sits in the middle of the pore. The result is a molecular machine – a ring-like assembly of seven subunits, one of which has been modified to clamp the cyclodextrin -- that recognizes virtually every base passing through the pore.

By altering variables such as salt concentration, pH and temperature, Clarke and colleagues found conditions that allowed them to resolve the four bases to an accuracy of about 99.8%. The slight difference in size of the four bases results in a discrete blockage of the pore, which is read as a reproducible dip in the applied current from a baseline of around 60 picoamps to anywhere from 20-40 picoamps. In the current system, bases can be identified as they flow through the nanopore at a rate of about 25 per second.

Next Steps

Clarke and colleagues conclude that they have “solve[d] the key technical problems required for real-time, high-resolution nucleoside monophosphate detection.” They go on to state: “These advances represent the realization of a complete nanopore base detector, which, when combined with a compatible exonuclease DNA processing system, will provide the basis of a complete nanopore sequencer.”

That indeed is the next crucial step for Oxford Nanopore – to couple an exonuclease enzyme to the nanopore so that single bases are cleaved off a template DNA strand and their identity read off instantaneously as they funnel through the nanopore. Clark and colleagues conclude the Nature Nanotechnology paper by showing that the nanopore does indeed work in salt conditions favoring exonuclease activity and can detect bases cleaved off DNA strands in solution by the enzyme.

Oxford Nanopore was founded in 2005 and is located on the outskirts of Oxford, UK. Last month, the company announced an $18-million sales and distribution deal with Illumina for its exonuclease-based sequencing technology.

Editor’s note: Oxford Nanopore’s James Clarke will be presenting a poster on this work at CHI’s Next-Generation Sequencing conference, March 17-19, in San Diego.

*FURTHER READING: Clarke, J. et al. “Continuous base identification for single-molecule nanopore DNA sequencing.” Nature Nanotech. 2009.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

oracle_clinical
eClinical Visions - Clinical Trial Management: Enabling Operational Efficiency
Sponsored by Oracle

Read how contributors from Genzyme, Duke Clinical Research Institute, Accenture, Oracle Health Sciences and others address some of the most pertinent challenges facing the biopharmaceutical industry including... Globalization of clinical trials driven by the need to reduce costs and recruit participants; greater outsourcing; escalating regulatory demands; increased trial complexity; and post-marketing studies. Download this paper to gain new insight into:

  • Recent progress made in addressing these challenges
  • Expert opinion on clinical trial management systems (CTMS) for improving trial efficiencies
  • How to cut trial costs and enhance the productivity of trial participants


oracle_RDC
Remote Data Capture – Acquisition and Analysis
Sponsored by Oracle

Today nearly half of all clinical trials are conducted electronically, and rising! Electronic Data Capture (EDC) technology provides industry-wide opportunities, along with challenges, that are being addressed. In this informative report industry experts and users from Pfizer, PPD, C3i and Oracle Health Sciences discuss the impact of EDC and its newest zero footprint; online iteration.  It can used anywhere, world-wide, where the Internet is available while placing greater onus on global trial support. The critical focus of this new technology is that it must support the work of the person at the heart of the clinical trial system– the investigator. Download this report to learn more about:

  • Trends and Issues in an Electronic Clinical Data Management World
  • The New Remote Data Capture Paradigm 
  • Improving and Monitoring Clinical Data Management in the eClinical Age
  • Optimizing and Supporting Remote Data Capture


oracle_video
Technology Video Report: A Day in the Life with Remote Data Capture (Next-Gen EDC)
Sponsored by Oracle
See why Oracle Remote Data Capture (RDC) Onsite is the next generation in electronic data capture with its user-friendly method to collect, clean, review, and verify clinical trial data. Providing unprecedented performance with real-time data capture, Oracle RDC Onsite simplifies source data verification. With a clear, consistent view of study data across all sites, the benefits include reduced monitoring time, decreased queries and discrepancies, and less time to database lock.



Life Science Webcasts & Podcasts

Predict or Perish! Shaping the Practices of Clinical Trials
Decisionview webinarSponsored by:  DecisionView

Predictive Analytics are a key differentiator in running your clinical trials successfully through 2010 and beyond. They will help you to optimize your patient enrollment, reduce your clinical operations costs and minimize your financial liability in the clinical supply chain. In this session, you will:
• Learn what predictive analytics are and what they are not
• Understand why you need predictive analytics to run your clinical trials, and
• Explore how predictive analytics will shape the future of clinical trials

Download Now. 

 



More Podcasts

Job Openings

The University of Washington Department of Genome Sciences is seeking a LINUX SYSTEMS ENGINEERING MANAGER to lead a team in a diverse scientific computing environment that includes multiple HPC systems, petascale storage, and custom application servers. Apply online at UW Hires for req number 61505.  http://www.washington.edu/admin/hr/jobs/

Loading...

For reprints and/or copyright permission, please contact The YGS Group, 3650 West Market Street, York, PA;

(717) 505-9701 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.